STOCK TITAN

VIADERMA INC - VDRM STOCK NEWS

Welcome to our dedicated page for VIADERMA news (Ticker: VDRM), a resource for investors and traders seeking the latest updates and insights on VIADERMA stock.

Viaderma Inc (VDRM) is a biotechnology company focused on rapidly introducing new products to the pharmaceutical industry through innovative research and development. They specialize in selling medical products related to infectious diseases and pain management. The company is currently undergoing stability testing for their lead product Vitastem Ultra, with plans to distribute it in multiple countries. Viaderma is also finalizing FDA-registered approval for their hair regrowth product, Nupelo. Furthermore, they are working on scaling product inventory with a new manufacturing facility to meet increasing demand, overcoming scalability challenges faced previously. Viaderma is dedicated to expanding its business and achieving new heights in the pharmaceutical market.

Rhea-AI Summary

ViaDerma (OTC Pink: VDRM), a transdermal drug delivery and topical antibiotic products company, reports significant achievements in 2024. The company has expanded its workforce to 13 professionals, with 6 employees in the United States and 7 abroad, operating across seven countries. A major milestone includes the successful completion of a one-million-unit order to Nigeria, delivered in two shipments of 500,000 units each in August and October 2024. The company positions these achievements as groundwork for further expansion in 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
none
-
Rhea-AI Summary

ViaDerma, Inc. (OTC Pink: VDRM) reported strong financial results for Q2 2024, achieving positive net income and significant cash flow growth. Key highlights include:

- Steady revenues of $300,191 for H1 2024
- Net income of $54,008 for the six-month period, a 171.5% increase from the previous year
- Cash reserves surged to $826,175, a 7,972% increase from year-end 2023
- Total liabilities reduced by 5.3% to $1,096,509

The company's lead product, Vitastem, an FDA-registered topical antibiotic, continues to gain market traction. ViaDerma is advancing its product pipeline in anti-aging skincare, pain management, and other areas. The company is also adopting a wholesale distribution model and exploring joint ventures to expand its market presence.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.55%
Tags
-
Rhea-AI Summary

ViaDerma (OTC: VDRM) has successfully shipped 500,000 units of its tetracycline-based topical antibiotic to Nigeria, marking a significant milestone in its international expansion. The shipment was completed as planned by the end of August 2024. A second shipment of an additional 500,000 units is expected to be dispatched by the end of October 2024, demonstrating the company's commitment to consistent supply.

CEO Dr. Christopher Otiko recently returned from a productive follow-up trip to Dubai, where he engaged with key partners, solidifying plans to expand distribution across the Middle East. ViaDerma's innovative products, including patented transdermal delivery systems, have been well-received in international markets, addressing the growing need for effective wound care solutions in underserved regions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.4%
Tags
none
Rhea-AI Summary

ViaDerma, Inc. (OTC: VDRM) has announced a significant milestone in its global expansion efforts. The company is preparing to ship 500,000 units of its flagship tetracycline-based topical antibiotic to Nigeria by the end of August 2024, with a follow-up delivery expected in November 2024. This move marks ViaDerma's strategic push into the African market.

Additionally, ViaDerma has begun the registration process in Kenya, Namibia, and Tanzania, signaling its entry into East and Southern Africa. The company is also preparing registration applications for seven other countries across Africa, Europe, and the Middle East. CEO Dr. Christopher Otiko will be traveling to Dubai to finalize key initiatives with regional partners, focusing on strengthening partnerships and expanding distribution throughout the Middle East.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

ViaDerma, Inc. (OTC Pink: VDRM) has announced significant developments in its global expansion strategy. The company has finalized distribution agreements with two leading companies in Dubai, aimed at expanding the availability of its flagship topical antibiotic product, Vitastem, in the Middle East and Eastern Europe. To support this growth, ViaDerma has made six key hires, including a Business Development Analyst, Project Manager, HR Specialist, Fractional COO, and a Regulatory Specialist with FDA experience. A new Chief Technology Officer is also set to join soon.

Dr. Christopher Otiko, President of ViaDerma, expressed optimism about the company's future growth prospects and hinted at a forthcoming announcement regarding a large international shipment of Vitastem. These strategic moves position ViaDerma for significant expansion beyond the United States market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25%
Tags
management
-
Rhea-AI Summary

ViaDerma (OTC Pink: VDRM) released its quarterly report for the period ending March 31, 2024, showcasing significant financial improvements. The company experienced a 3700% increase in cash on hand, rising from $9,933 to $377,901 compared to the previous year.

Gross profits saw a slight uptick, while operating expenses were reduced by 52%, from $93,356 to $44,744. In a noteworthy move, CEO Dr. Christopher Otiko provided a $700,000 loan to the company, which he repaid in full by May 28, 2024.

ViaDerma currently holds approximately $1 million in cash, sufficient to fund ongoing operations without incurring debt. Additionally, the company is hiring three new full-time employees to boost international sales, reflecting its robust financial health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.67%
Tags
Rhea-AI Summary
ViaDerma, Inc. announces business updates including progress in stability testing for Vitastem Ultra, ramping up production capabilities, and plans for international distribution. FDA registration for Nupelo is on hold, but the company is exploring alternative natural active ingredients. ViaDerma is also in talks with the VA and a large HMO for distribution. Licensing agreements have been expanded to 14 states.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

ViaDerma, Inc. (OTC Pink: VDRM) has announced the brand name Nupelo for its upcoming minoxidil hair regrowth product. The company recently submitted an application for FDA registration, expected to be completed within weeks. Nupelo will utilize ViaDerma’s proprietary dual carrier transdermal delivery technology, aimed at effectively regrowing hair rather than just reducing hair loss. The product is set to launch for purchase online by the end of Q2 2023, with availability on various platforms including nupelo.com. CEO Dr. Chris Otiko highlighted the speed and effectiveness of the development process.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30%
Tags
none
Rhea-AI Summary

ViaDerma, Inc. (VDRM) announced plans to launch a new hair regrowth product using Minoxidil with a proprietary transdermal delivery technology. This technology enhances absorption, significantly outperforming traditional treatments. The global hair restoration market is projected to reach $13.6 billion by 2028, while the Minoxidil market is expected to grow to $1.43 billion during the same time frame. FDA registration for the product is anticipated within 90 days, aiming for market availability later this year. CEO Dr. Chris Otiko expressed excitement about entering this expanding industry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
none

FAQ

What is the current stock price of VIADERMA (VDRM)?

The current stock price of VIADERMA (VDRM) is $0.008 as of December 23, 2024.

What is the market cap of VIADERMA (VDRM)?

The market cap of VIADERMA (VDRM) is approximately 11.1M.

What is Viaderma Inc (VDRM) known for?

Viaderma is known for its focus on introducing new products to the pharmaceutical industry through innovative research and development, particularly in the fields of infectious diseases and pain management.

What is the current status of Vitastem Ultra?

Viaderma is in the final stages of stability testing for Vitastem Ultra, their lead product, in order to distribute it in multiple countries.

What progress has been made with FDA-registered approval for Nupelo?

Viaderma is finalizing FDA-registered approval for their hair regrowth product, Nupelo, and is exploring alternative natural ingredients to accelerate the process.

How is Viaderma addressing product inventory scalability?

The company is working on scaling product inventory through a new manufacturing facility to meet increasing demand and has overcome scalability challenges faced with a previous manufacturer.

What are the future plans for Viaderma?

Viaderma is committed to expanding its business and achieving new heights in the pharmaceutical market with a strong focus on product innovation and meeting customer demand.

VIADERMA INC

OTC:VDRM

VDRM Rankings

VDRM Stock Data

11.10M
983.56M
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Marina del Rey